Dose recommendations for intravenous colistin in pediatric patients from a prospective, multicenter, population pharmacokinetic study
Objectives: The aim of this study was to describe the population pharmacokinetics of intravenous colistin use in children and to propose optimal dosage regimens. Methods: A prospective, multicenter, population pharmacokinetic (PPK) study was conducted. Phoenix 64 version 8.3 was used for the PPK ana...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-08-01
|
Series: | International Journal of Infectious Diseases |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971221005397 |
_version_ | 1818661639718699008 |
---|---|
author | Noppadol Wacharachaisurapol Warumphon Sukkummee Orawan Anunsittichai Panida Srisan Siriporn Sangkhamal Prawat Chantharit Warunee Punpanich Vandepitte Thitima Wattanavijitkul Thanyawee Puthanakit |
author_facet | Noppadol Wacharachaisurapol Warumphon Sukkummee Orawan Anunsittichai Panida Srisan Siriporn Sangkhamal Prawat Chantharit Warunee Punpanich Vandepitte Thitima Wattanavijitkul Thanyawee Puthanakit |
author_sort | Noppadol Wacharachaisurapol |
collection | DOAJ |
description | Objectives: The aim of this study was to describe the population pharmacokinetics of intravenous colistin use in children and to propose optimal dosage regimens. Methods: A prospective, multicenter, population pharmacokinetic (PPK) study was conducted. Phoenix 64 version 8.3 was used for the PPK analysis. Simulations were performed to estimate the probability of target attainment for patients achieving target plasma colistin average steady-state concentrations (Css,avg). Results: A total of 334 plasma colistin concentrations were obtained from 79 pediatric patients with a median age (interquartile range) of 2.6 years (0.8−6.8 years); 73 (92.4%) were admitted to intensive care units. Colistin pharmacokinetics were adequately described by a one-compartment model with first-order elimination along with serum creatinine (SCr) as a significant covariate in colistin clearance. The simulation demonstrated that the recommended dose of 5 mg of colistin base activity (CBA)/kg/day resulted in 18.2−63.0% probability of achieving a target Css,avg of 2 mg/l. With a lower targeted Css,avg of 1 mg/l, colistin dosing with 7.5 mg and 5 mg of CBA/kg/day were adequate for children with SCr levels of 0.1−0.3 mg/dl and >0.3 mg/dl, respectively. Conclusions: SCr is a significant covariate in colistin clearance in children. Colistin dosing should be selected according to the patient's SCr level and the desired target Css,avg. |
first_indexed | 2024-12-17T04:48:16Z |
format | Article |
id | doaj.art-1db2e00ec03b4a60a3c2d765722a6bd0 |
institution | Directory Open Access Journal |
issn | 1201-9712 |
language | English |
last_indexed | 2024-12-17T04:48:16Z |
publishDate | 2021-08-01 |
publisher | Elsevier |
record_format | Article |
series | International Journal of Infectious Diseases |
spelling | doaj.art-1db2e00ec03b4a60a3c2d765722a6bd02022-12-21T22:02:59ZengElsevierInternational Journal of Infectious Diseases1201-97122021-08-01109230237Dose recommendations for intravenous colistin in pediatric patients from a prospective, multicenter, population pharmacokinetic studyNoppadol Wacharachaisurapol0Warumphon Sukkummee1Orawan Anunsittichai2Panida Srisan3Siriporn Sangkhamal4Prawat Chantharit5Warunee Punpanich Vandepitte6Thitima Wattanavijitkul7Thanyawee Puthanakit8Clinical Pharmacokinetics and Pharmacogenomics Research Unit, Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, Bangkok, ThailandClinical Pharmacokinetics and Pharmacogenomics Research Unit, Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, Bangkok, ThailandCentre of Excellence for Pediatric Infectious Diseases and Vaccines, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, ThailandDivision of Pulmonary and Critical Care, Department of Pediatrics, Queen Sirikit National Institute of Child Health, Bangkok, ThailandPediatric Intensive Care Unit, Queen Sirikit National Institute of Child Health, Bangkok, ThailandDivision of Infectious Diseases, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, ThailandQueen Sirikit National Institute of Child Health, Bangkok, Thailand; College of Medicine, Rangsit University, Bangkok, ThailandDepartment of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, ThailandCentre of Excellence for Pediatric Infectious Diseases and Vaccines, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Corresponding author: Thanyawee Puthanakit, Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, 1873 Rama IV Road, Pathumwan, Bangkok, Thailand, 10330. Tel: +6622564930.Objectives: The aim of this study was to describe the population pharmacokinetics of intravenous colistin use in children and to propose optimal dosage regimens. Methods: A prospective, multicenter, population pharmacokinetic (PPK) study was conducted. Phoenix 64 version 8.3 was used for the PPK analysis. Simulations were performed to estimate the probability of target attainment for patients achieving target plasma colistin average steady-state concentrations (Css,avg). Results: A total of 334 plasma colistin concentrations were obtained from 79 pediatric patients with a median age (interquartile range) of 2.6 years (0.8−6.8 years); 73 (92.4%) were admitted to intensive care units. Colistin pharmacokinetics were adequately described by a one-compartment model with first-order elimination along with serum creatinine (SCr) as a significant covariate in colistin clearance. The simulation demonstrated that the recommended dose of 5 mg of colistin base activity (CBA)/kg/day resulted in 18.2−63.0% probability of achieving a target Css,avg of 2 mg/l. With a lower targeted Css,avg of 1 mg/l, colistin dosing with 7.5 mg and 5 mg of CBA/kg/day were adequate for children with SCr levels of 0.1−0.3 mg/dl and >0.3 mg/dl, respectively. Conclusions: SCr is a significant covariate in colistin clearance in children. Colistin dosing should be selected according to the patient's SCr level and the desired target Css,avg.http://www.sciencedirect.com/science/article/pii/S1201971221005397ColistinPharmacokineticsPediatricsMultidrug-resistant bacteria |
spellingShingle | Noppadol Wacharachaisurapol Warumphon Sukkummee Orawan Anunsittichai Panida Srisan Siriporn Sangkhamal Prawat Chantharit Warunee Punpanich Vandepitte Thitima Wattanavijitkul Thanyawee Puthanakit Dose recommendations for intravenous colistin in pediatric patients from a prospective, multicenter, population pharmacokinetic study International Journal of Infectious Diseases Colistin Pharmacokinetics Pediatrics Multidrug-resistant bacteria |
title | Dose recommendations for intravenous colistin in pediatric patients from a prospective, multicenter, population pharmacokinetic study |
title_full | Dose recommendations for intravenous colistin in pediatric patients from a prospective, multicenter, population pharmacokinetic study |
title_fullStr | Dose recommendations for intravenous colistin in pediatric patients from a prospective, multicenter, population pharmacokinetic study |
title_full_unstemmed | Dose recommendations for intravenous colistin in pediatric patients from a prospective, multicenter, population pharmacokinetic study |
title_short | Dose recommendations for intravenous colistin in pediatric patients from a prospective, multicenter, population pharmacokinetic study |
title_sort | dose recommendations for intravenous colistin in pediatric patients from a prospective multicenter population pharmacokinetic study |
topic | Colistin Pharmacokinetics Pediatrics Multidrug-resistant bacteria |
url | http://www.sciencedirect.com/science/article/pii/S1201971221005397 |
work_keys_str_mv | AT noppadolwacharachaisurapol doserecommendationsforintravenouscolistininpediatricpatientsfromaprospectivemulticenterpopulationpharmacokineticstudy AT warumphonsukkummee doserecommendationsforintravenouscolistininpediatricpatientsfromaprospectivemulticenterpopulationpharmacokineticstudy AT orawananunsittichai doserecommendationsforintravenouscolistininpediatricpatientsfromaprospectivemulticenterpopulationpharmacokineticstudy AT panidasrisan doserecommendationsforintravenouscolistininpediatricpatientsfromaprospectivemulticenterpopulationpharmacokineticstudy AT siripornsangkhamal doserecommendationsforintravenouscolistininpediatricpatientsfromaprospectivemulticenterpopulationpharmacokineticstudy AT prawatchantharit doserecommendationsforintravenouscolistininpediatricpatientsfromaprospectivemulticenterpopulationpharmacokineticstudy AT waruneepunpanichvandepitte doserecommendationsforintravenouscolistininpediatricpatientsfromaprospectivemulticenterpopulationpharmacokineticstudy AT thitimawattanavijitkul doserecommendationsforintravenouscolistininpediatricpatientsfromaprospectivemulticenterpopulationpharmacokineticstudy AT thanyaweeputhanakit doserecommendationsforintravenouscolistininpediatricpatientsfromaprospectivemulticenterpopulationpharmacokineticstudy |